seekingalpha.com · 4 jul

UnitedHealth: Patience Could Be Rewarded

UnitedHealth Group remains undervalued and is positioned as a strong long-term investment despite recent price appreciation and operational challenges. Management maintains a long-term growth algorithm of 13–16% bottom-line growth, driven by margin recovery, AI investments, and capital allocation including share buybacks. Current valuation models, even with conservative growth assumptions, suggest significant intrinsic value upside, but recent rapid price gains may limit short-term upside.

fool.com · 3 jul

Members of Congress Are Loading Up on Johnson & Johnson and UnitedHealth. Here's Why Retail Investors Should Pay Attention.

Rep. Lisa McClain (R-Mich.) has been a big buyer of Johnson & Johnson stock.

seekingalpha.com · 2 jul

UnitedHealth Group: The Turnaround Continues Into The Q2 Report

UnitedHealth Group is reiterated as a buy, with a raised price target near $460, reflecting improved earnings guidance and operational turnaround. Q1 results beat expectations, with non-GAAP EPS of $7.23 and revenue of $111.7B, prompting an FY 2026 EPS outlook above $18.25 and a $2B buyback. UNH benefits from strong free cash flow, a 2.18% yield, positive EPS revisions, and strategic investments in modernization and AI.

zacks.com · 2 jul

UnitedHealth Group Incorporated (UNH) is Attracting Investor Attention: Here is What You Should Know

UnitedHealth (UNH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

fool.com · 2 jul

1 Magnificent ETF I'm Buying Hand Over Fist in 2026

This ETF has historically delivered excellent returns.

fool.com · 2 jul

UnitedHealth Is Spending $3 Billion on AI and Getting $2 Back for Every $1. Why That Changes the Bull Case for This Blue Chip Stock.

AI is becoming a meaningful earnings driver for UnitedHealth. Automation is reducing costs across healthcare administration.

businesswire.com · 1 jul

UnitedHealth Group Now Covers Guardant Health's Shield Blood Test for Colorectal Cancer Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) is now covered for eligible UnitedHealth Group (UHG) members1, making it the first major commercial insurer to provide coverage for adults 45 or older amid rising CRC rates for adults under 652 and mortality for younger adults as the leading cause of cancer death for those under 50.3 Shield is the first and onl.

fool.com · 1 jul

Schwab vs. Vanguard: Which Dividend ETF Is Best for Your Portfolio?

Portfolio concentration and sector weightings set these two popular income funds apart for investors seeking steady cash flow.